Dr. Lal Path Labs , a leading diagnostic services provider in India, has received an Assessment Order and Demand Notice from the Income Tax Department, the company disclosed in a recent filing. The order, pertaining to the financial year 2017-18, includes additions and disallowances amounting to ₹2.79 crore, resulting in an income tax demand of ₹2.43 crore.

Details of the Assessment Order

The company received the order on October 31, which outlines the following key points:

Company's Response

Dr. Lal PathLabs has stated that the tax demand does not have a material impact on its financials, operations, or other activities beyond the mentioned amount. The company is currently examining the order and plans to take appropriate steps, which may include filing an appeal against the assessment.

Investor Implications

While the tax demand is significant, it represents a relatively small fraction of the company's overall financial position. In its latest financial results, Dr. Lal PathLabs reported:

• Revenue of ₹731.00 crore
• EBITDA of ₹224.00 crore
• PAT of ₹152.00 crore

The tax demand of ₹2.43 crore is approximately 1.60% of the company's quarterly profit after tax, suggesting a limited immediate financial impact.

Looking Ahead

As Dr. Lal PathLabs navigates this tax issue, investors and stakeholders will be watching closely to see how the company addresses the demand and what impact, if any, it may have on future financial statements. The company's approach to resolving this matter could provide insights into its financial management and regulatory compliance strategies.

Dr. Lal PathLabs continues to maintain a strong market position in the diagnostic services sector, with a wide network of laboratories and patient service centers across India. The company's ability to manage regulatory challenges while maintaining its growth trajectory will be crucial for its long-term success in the competitive healthcare diagnostics market.

Dr. Lal Path Labs , a leading diagnostic and related healthcare service provider, has made significant announcements regarding shareholder benefits, including the confirmation of key dates for its bonus share issue.

Bonus Share Issue - Key Dates Confirmed

The Board of Directors has fixed December 19, 2025 as the record date for determining shareholder eligibility for the bonus share issue. The company announced a bonus share issue in the ratio of 1:1, meaning shareholders will receive one new fully paid-up equity share for every existing share they hold.

The deemed date of allotment for bonus equity shares has been set as December 22, 2025, in accordance with SEBI circular no. CIR/CFD/PoD/2024/122 dated September 16, 2024.

Second Interim Dividend Declaration

The Board of Directors, in their meeting held on October 31, 2025, approved a second interim dividend of ₹7.00 per equity share. This dividend represents 70% of the face value of ₹10.00 per share for the financial year 2025-26.

Authorized Share Capital Enhancement

To facilitate the bonus issue, the company has increased its authorized share capital from ₹1,07,96,00,000 to ₹2,00,00,00,000, subject to shareholders' approval. The bonus shares will be issued from the company's Securities Premium Account, which stood at ₹1,247.85 million as per the audited financial statements for the year ended March 31, 2025.

Recent Financial Performance

For the quarter ended September 30, 2025, Dr. Lal PathLabs reported consolidated revenue of ₹7,548.00 million and profit after tax of ₹1,333.00 million.

The company expects to credit/dispatch the bonus shares within two months from the date of board approval, i.e., by December 30, 2025. Shareholders whose names appear in the Register of Members or List of Beneficial Owners as received from NSDL and CDSL on the record date will be eligible for the bonus shares.